Published in Gene Therapy Weekly, August 31st, 2000
According to the company, the test results clearly demonstrated the ability of Medi-Ject's needle-free injection system to deliver BioSante's particle-based vaccine adjuvant system (CAP) to the targeted intra-muscular injection site. The tests were conducted with DNA encoding viral proteins formulated with BioSante's proprietary vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.